tetano
Editor, Senior Moderator
Biochem Biophys Res Commun. 2013 Oct 15. pii: S0006-291X(13)01713-0. doi: 10.1016/j.bbrc.2013.10.041. [Epub ahead of print]
A monoclonal Antibody Targeting a Highly Conserved Epitope in Influenza B Neuraminidase Provides Protection against Drug Resistant Strains.
Doyle TM, Li C, Bucher DJ, Hashem AM, Van Domselaar G, Wang J, Farnsworth A, She YM, Cyr T, He R, Brown EG, Hurt AC, Li X.
Source
Centre for Vaccine Evaluation, Biologics and Genetic Therapies Directorate, HPFB, Health Canada, Ottawa, ON, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Abstract
All influenza viral neuraminidases (NA) of both type A and B viruses have only one universally conserved sequence located between amino acids 222-230. A monoclonal antibody against this region has been previously reported to provide broad inhibition against all nine subtypes of influenza A NA; yet its inhibitory effect against influenza B viral NA remained unknown. Here, we report that the monoclonal antibody provides a broad inhibition against various strains of influenza B viruses of both Victoria and Yamagata genetic lineage. Moreover, the growth and NA enzymatic activity of two drug resistant influenza B strains (E117D and D197E) are also inhibited by the antibody even though these two mutations are conformationally proximal to the universal epitope. Collectively, these data suggest that this unique, highly-conserved linear sequence in viral NA is exposed sufficiently to allow access by inhibitory antibody during the course of infection; it could represent a potential target for antiviral agents and vaccine-induced immune responses against diverse strains of type B influenza virus.
Copyright ? 2013. Published by Elsevier Inc.
KEYWORDS:
Cross-protection, Influenza B, Neuraminidase, Universal antibody, Vaccination
PMID:
24140051
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24140051
A monoclonal Antibody Targeting a Highly Conserved Epitope in Influenza B Neuraminidase Provides Protection against Drug Resistant Strains.
Doyle TM, Li C, Bucher DJ, Hashem AM, Van Domselaar G, Wang J, Farnsworth A, She YM, Cyr T, He R, Brown EG, Hurt AC, Li X.
Source
Centre for Vaccine Evaluation, Biologics and Genetic Therapies Directorate, HPFB, Health Canada, Ottawa, ON, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Abstract
All influenza viral neuraminidases (NA) of both type A and B viruses have only one universally conserved sequence located between amino acids 222-230. A monoclonal antibody against this region has been previously reported to provide broad inhibition against all nine subtypes of influenza A NA; yet its inhibitory effect against influenza B viral NA remained unknown. Here, we report that the monoclonal antibody provides a broad inhibition against various strains of influenza B viruses of both Victoria and Yamagata genetic lineage. Moreover, the growth and NA enzymatic activity of two drug resistant influenza B strains (E117D and D197E) are also inhibited by the antibody even though these two mutations are conformationally proximal to the universal epitope. Collectively, these data suggest that this unique, highly-conserved linear sequence in viral NA is exposed sufficiently to allow access by inhibitory antibody during the course of infection; it could represent a potential target for antiviral agents and vaccine-induced immune responses against diverse strains of type B influenza virus.
Copyright ? 2013. Published by Elsevier Inc.
KEYWORDS:
Cross-protection, Influenza B, Neuraminidase, Universal antibody, Vaccination
PMID:
24140051
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24140051